Borgeson Blake
Director · RXRX
As of 2026-09-27, Borgeson Blake has 39 Form 4 transactions on record across 1 company — 11 in the trailing 12 months.
Everything this person has disclosed to the SEC on Form 4 — across every company they file for — reconstructed from the public record. A filing history, not a tip sheet.
Pattern in the record: open-market sales filed in September in multiple years since 2024 — a recurring calendar cadence, more consistent with scheduled activity than a one-off decision.
Reconstructed holdings
- Direct $23.0M
- Indirect $0
| RXRX | direct | 6,158,287 sh | $23.0M |
Reconstructed from this person's own Form 4 filings — the total each filing reported owning afterward, priced at the close on the as-of date shown. A filed position can lag the real one.
Direct and indirect holdings (e.g. through a trust or fund) are tagged separately, as filed.
Trades by company
Filing ledger
| Date | Company | Action | Shares @ price | Value | Ownership Δ | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | RXRX | Sale | 30,000 @ $3.34 | $100K | −0.5% of holding | 6,158,287 | Form 4 |
| 2026-08-04 | RXRX | Sale | 30,000 @ $3.25 | $98K | −0.5% of holding | 6,188,287 | Form 4 |
| 2026-07-07 | RXRX | Sale | 40,000 @ $3.96 | $159K | −0.6% of holding | 6,218,287 | Form 4 |
| 2026-06-02 | RXRX | Sale | 30,000 @ $3.68 | $110K | −0.5% of holding | 6,169,863 | Form 4 |
| 2026-05-05 | RXRX | Sale | 30,000 @ $3.52 | $106K | −0.5% of holding | 6,199,863 | Form 4 |
| 2026-04-07 | RXRX | Sale | 30,000 @ $3.10 | $93K | −0.5% of holding | 6,229,863 | Form 4 |
| 2026-03-03 | RXRX | Sale | 170,000 @ $3.46 | $588K | −2.6% of holding | 6,259,863 | Form 4 |
| 2026-02-03 | RXRX | Sale | 220,000 @ $4.20 | $924K | −3.3% of holding | 6,429,863 | Form 4 |
| 2026-01-06 | RXRX | Sale | 220,000 @ $4.36 | $959K | −3.2% of holding | 6,649,863 | Form 4 |
| 2025-12-02 | RXRX | Sale | 220,000 @ $4.37 | $961K | −3.1% of holding | 6,869,863 | Form 4 |
| 2024-11-12 | RXRX | Sale | 11,447 @ $7.64 | $87K | −0.2% of holding | 7,066,113 | Form 4 |
| 2024-10-29 | RXRX | Sale | 11,447 @ $6.72 | $77K | −0.2% of holding | 7,077,560 | Form 4 |
| 2024-10-15 | RXRX | Sale | 11,447 @ $6.67 | $76K | −0.2% of holding | 7,089,007 | Form 4 |
| 2024-10-01 | RXRX | Sale | 11,447 @ $6.22 | $71K | −0.2% of holding | 7,098,428 | Form 4 |
| 2024-09-17 | RXRX | Sale | 11,447 @ $6.84 | $78K | −0.2% of holding | 7,109,875 | Form 4 |
| 2024-09-03 | RXRX | Sale | 11,447 @ $6.27 | $72K | −0.2% of holding | 7,121,322 | Form 4 |
| 2024-08-20 | RXRX | Sale | 11,447 @ $7.12 | $82K | −0.2% of holding | 7,132,769 | Form 4 |
| 2024-08-06 | RXRX | Sale | 11,447 @ $6.82 | $78K | −0.2% of holding | 7,144,216 | Form 4 |
| 2024-07-23 | RXRX | Sale | 11,447 @ $8.48 | $97K | −0.2% of holding | 7,155,663 | Form 4 |
| 2024-07-09 | RXRX | Sale | 11,447 @ $7.32 | $84K | −0.2% of holding | 7,167,110 | Form 4 |
| 2024-06-25 | RXRX | Sale | 11,447 @ $9.51 | $109K | −0.2% of holding | 7,177,116 | Form 4 |
| 2024-06-11 | RXRX | Sale | 11,447 @ $8.45 | $97K | −0.2% of holding | 7,188,563 | Form 4 |
| 2024-05-28 | RXRX | Sale | 11,447 @ $9.17 | $105K | −0.2% of holding | 7,186,913 | Form 4 |
| 2024-05-14 | RXRX | Sale | 20,054 @ $10.12 | $203K | −0.3% of holding | 7,198,360 | Form 4 |
| 2024-04-30 | RXRX | Sale | 11,447 @ $7.95 | $91K | −0.2% of holding | 7,218,414 | Form 4 |
| 2024-04-16 | RXRX | Sale | 11,447 @ $7.66 | $88K | −0.2% of holding | 7,229,861 | Form 4 |
| 2024-04-02 | RXRX | Sale | 11,447 @ $8.82 | $101K | −0.2% of holding | 7,241,308 | Form 4 |
| 2024-03-19 | RXRX | Sale | 20,054 @ $10.79 | $216K | −0.3% of holding | 7,252,755 | Form 4 |
| 2024-03-05 | RXRX | Sale | 20,054 @ $12.06 | $242K | −0.3% of holding | 7,272,809 | Form 4 |
| 2024-02-20 | RXRX | Sale | 19,745 @ $12.31 | $243K | −0.3% of holding | 7,293,172 | Form 4 |
| 2024-02-20 | RXRX | Sale | 309 @ $13.04 | $4K | −0.0% of holding | 7,292,863 | Form 4 |
8 award / exercise / gift records — not counted as purchases
| Date | Company | Action | Shares | Owned after | Filing |
|---|---|---|---|---|---|
| 2026-06-17 | RXRX | Award / grant | 88,424 | 6,258,287 | Form 4 |
| 2025-06-18 | RXRX | Award / grant | 44,031 | 44,031 | Form 4 |
| 2025-06-18 | RXRX | Award / grant | 22,016 | 7,089,863 | Form 4 |
| 2025-01-02 | RXRX | Award / grant | 1,734 | 7,067,847 | Form 4 |
| 2024-10-01 | RXRX | Award / grant | 2,026 | 7,100,454 | Form 4 |
| 2024-07-01 | RXRX | Award / grant | 1,441 | 7,178,557 | Form 4 |
| 2024-06-03 | RXRX | Award / grant | 13,097 | 7,200,010 | Form 4 |
| 2024-06-03 | RXRX | Award / grant | 26,193 | 26,193 | Form 4 |
Source: SEC Form 4 filings. Each row links to its original filing.
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.